Revenue
No reported data
ANAVEX LIFE SCIENCES CORP. (AVXL)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2014
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & development | $37.6M | $41.8M | $43.7M | $37.9M | $33.0M | $25.2M | $22.3M | $13.3M | $10.7M | $7.3M | $2.3M | $732,395 | $263,847 | $2.7M | $2.6M | $2.7M | — | — | — | — | — |
| Operating expenses | $51.4M | $52.9M | $55.8M | $51.0M | $42.0M | $31.1M | $29.1M | $19.3M | $15.7M | $15.6M | $7.1M | $3.0M | — | — | — | — | — | — | — | — | — |
| Operating income | −$51.4M | −$52.9M | −$55.8M | −$51.0M | −$42.0M | −$31.1M | — | — | — | — | — | −$3.0M | −$2.1M | −$4.3M | −$6.2M | −$5.6M | — | — | — | — | — |
| EBITDAderived | — | — | — | — | — | — | — | — | — | — | — | −$3.0M | −$2.1M | −$4.3M | −$6.2M | −$5.6M | — | — | — | — | — |
| Net income | −$46.4M | −$43.0M | −$47.5M | −$48.0M | −$37.9M | −$26.3M | −$26.3M | −$17.3M | −$13.5M | −$14.7M | −$12.1M | −$10.0M | −$3.7M | −$8.3M | −$7.3M | −$8.8M | −$5.5M | −$5.4M | −$1.6M | −$25,532 | −$91,625 |
| Basic EPSper diluted share | -$0.54 | -$0.52 | -$0.60 | -$0.62 | -$0.54 | -$0.45 | -$0.54 | -$0.39 | -$0.33 | -$0.42 | -$0.65 | -$1.02 | -$0.12 | — | — | — | — | — | — | — | — |
| Diluted EPSper diluted share | -$0.54 | -$0.52 | -$0.60 | -$0.62 | -$0.54 | -$0.45 | -$0.54 | -$0.39 | -$0.33 | -$0.42 | -$0.65 | -$1.02 | -$0.12 | -$0.29 | -$0.29 | -$0.41 | — | — | — | — | — |